Evidence map›Paper›PMID 39501319›Full record

ArticleJournal of ovarian research2024

Progesterone peak influences embryonic developmental morphokinetics on trigger day? A retrospective study.

D Baldini, V M Bartoli, A Mastrorocco, D Ferri, M Dellino, A S Laganà, S Hatirnaz, G M Baldini, A Malvasi, A Vimercati and 1 more

Expression of concernAbstract read
In one paragraph

Article in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. The Trigger in IVF Cycles: Molecular Pathways and Clinical Implications.International journal of molecular sciences · 2025
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

D BaldiniMOMO' FertiLIFE, IVF Clinic, Bisceglie, 76011, Italy. dbaldini@libero.it.
V M BartoliDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, 70125, Italy.
A MastroroccoDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, 70125, Italy.
D FerriMOMO' FertiLIFE, IVF Clinic, Bisceglie, 76011, Italy.
M DellinoObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, Bari, 70124, Italy.
A S LaganàUnit of Obstetrics and Gynecology, Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties (PROMISE), "Paolo Giaccone" Hospital, University of Palermo, Palermo, 90127, Italy.
S HatirnazMediliv Medical Center, Ilkadim, Samsun, Turkey.
G M BaldiniObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, Bari, 70124, Italy.
A MalvasiObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, Bari, 70124, Italy.
A VimercatiObstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, Bari, 70124, Italy.
G TrojanoMadonna Delle Grazie Hospital ASM, Matera, 75100, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePremature Progesterone Rise (PPR) is characterized by elevated serum progesterone concentrations either towards the end of the follicular phase or on the trigger day, surpassing a pre-defined threshold value. Aim of the study is to evaluate the impact of PPR exceeding 1.5 ng/ml at the time of hCG-trigger on embryo morphokinetic parameters and to identify predictive biomarkers of in IntraCytoplasmic Sperm Injection (ICSI) cycles outcomes.

methodsIt is a retrospective study including patients underwent ICSI cycles in the period 2020-2023. 58 patients were recruited in the study group showing P levels in the trigger day greater than or equal to 1.5 ng/ml. A matching control group of 58 patients with P levels below 1.5 ng/ml was after selected. The general characteristics of these patients, including age, Body Mass Index (BMI), antral follicle count (AFC), anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels, the type of infertility and smoking/non-smoking patients, were recorded on the day of their initial visit. Subsequently, data were collected regarding the number of eggs retrieved, mature eggs, successfully fertilized eggs, and embryos reaching the blastocyst stage. Additionally, the timing of embryonic development and the quality of obtained blastocysts, as assessed by the degree of expansion and the characteristics of the inner cell mass (ICM) and trophectoderm (TE), were evaluated using Time-Lapse technology.

resultsElevated P levels exceeding 1.5 ng/ml on the trigger day were directly associated with a significantly larger number of antral follicles, consequently leading to a higher count of retrieved eggs, mature eggs, successfully fertilized eggs and embryos reaching the blastocyst stage. Furthermore, the analysis of morphokinetic parameters indicated faster division times and a notably greater number of high-grade blastocysts in the study group compared to the control group.

conclusionsP levels ≥ 1.5 ng/ml on the trigger day did not negatively impact embryonic morphokinetic parameters, instead resulting in faster embryo development in the initial stages.

Indexed as

Embryonic DevelopmentProgesteroneSperm Injections, IntracytoplasmicAdultEmbryo TransferFemaleFertilization in VitroHumansOvulation InductionPregnancyRetrospective StudiesProgesteroneEmbryo MorphokineticsIn vitro embryo cultureProgesterone peakTime-Lapse monitoring

Identifiers

PMID39501319
PMCPMC11536879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.